A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome)
https://doi.org/10.17650/1818-8346-2022-17-4-38-47
Abstract
Understanding the molecular biological basis of chronic lymphocytic leukemia (CLL) pathogenesis and stratification of patients into risk groups has now led to significant advances in treatment. New targeted drugs with different mechanisms of action (bruton’s tyrosine kinase inhibitors, bCL-2 inhibitors, pI3K inhibitors) have significantly improved the prognosis of high-risk CLL patients. In some CLL cases the nodular tumor component can change to a more aggressive subtype of lymphoma (often diffuse large b-cell) with preservation of the small-cell leukemic component with the CLL phenotype (Richter’s syndrome), usually characterized by rapid progression and poor prognosis. The issue of treatment efficacy in patients with Richter’s syndrome still remains unresolved. The results of new drugs clinical trials are often contradictory and cannot yet be recommended for routine use in clinical practice. The low incidence of Richter’s syndrome, the lack of a unified view of the pathogenesis and therapy approaches make the search for effective drugs an urgent task, so each clinical observation is of undoubted interest.
A clinical case of CLL patient with unfavorable molecular cytogenetic risk and transformation into diffuse large b-cell lymphoma (Richter’s syndrome) is presented. The combined use of bCL-2 inhibitors (venetoclax) and pI3K (duvelisib) led to the achievement of partial remission followed by a gradual increase in the positive antitumor effect.
About the Authors
O. A. Rukavitsyn
Main Military Clinical Hospital named after N.N. Burdenko, Ministry of Defense of Russia
Russian Federation
Russian Federation
Gospital’naya Ploshchad’, Moscow 105229
V. P. Pop
Main Military Clinical Hospital named after N.N. Burdenko, Ministry of Defense of Russia
Russian Federation
Russian Federation
Gospital’naya Ploshchad’, Moscow 105229
M. V. Drozd
Main Military Clinical Hospital named after N.N. Burdenko, Ministry of Defense of Russia
Russian Federation
Russian Federation
Gospital’naya Ploshchad’, Moscow 105229
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
References
1. Hallek M. Chronic lymphocytic leukemia. Klinicheskaya onkogematologiya = Clinical oncohematology 2010;3(1):101–2. (In Russ.).
2. Zakharova A.I., Obukhova T.N., Lorie Yu.Yu. et al. Cytogenetic aberrations in chronic Bcell lymphocytic leukemia and their relationship with clinical and biological features and disease prognosis. Terapevticheskiy arkhiv = Therapeutic archive 2006;78(7)57–62. (In Russ.).
3. Reindl L., Bacher U., Dicker F. et al. Biological and clinical characterization of recurrent 14q deletions in CLL and other mature Bcell neoplasms. Br J Haematol 2010;151(1):25–36. DOI: 10.1111/j.13652141.2010.08299.
4. Nikitin E.A., Severina N.A., Obukhova T.N. et al. TP53 gene aberrations in patients with chronic lymphocytic leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(4):316–22. (In Russ.).
5. Lin K.I., Tam C.S., Keating M.J. et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009;113(14):3168–71. DOI: 10.1182/blood200810184853
6. Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia. Berlin/Heidelberg, Germany: Springer, 2018.
7. Swerdlow S.H., Campo E., Harris N.L. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: International Agency for Research on Cancer, 2017.
8. Rossi D., Spina V., Gaidano G. Biology and treatment of Richter syndrome. Blood 2018;131(25):2761–72. DOI: 10.1182/ blood201801791376
9. Tsimberidou A.M., Keating M.J. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005;103(2):216–28. DOI: 10.1002/cncr.20773
10. Robak E., GoraTybor J., Kordek R. et al. Richter syndrome first manifesting as cutaneous Bcell lymphoma clonally distinct from primary Bcell chronic lymphocytic leukemia. Br J Dermatol 2005;153(4):833–7. DOI: 10.1111/j.13652133.2005.06805.x
11. Elnair R., Ellithi M., Kallam A. et al. Outcomes of Richter’s transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database. Ann Hematol 2021;100(10):2513–9. DOI: 10.1007/s0027702104603y
12. Parikh S.A., Rabe K.G., Call T.G. et al. Diffuse large Bcell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol 2013;162(6):774–82. DOI: 10.1111/bjh.12458
13. Fayad L., Robertson L.E., O’Brien S. et al. Hodgkin’s disease variant of Richter’s syndrome: experience at a single institution. Leuk Lymphoma 1996;23(2–4):333–7. DOI: 10.3109/10428199609054836
14. Marvyin K., Tjønnfjord E.B., Breland U.M., Tjønnfjord G.E. Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment. BMJ Case Rep 2020;13(9):e235816. DOI: 10.1136/bcr2020235816
15. Ansell S.M., Li C.Y., Lloyd R.V. et al. Epstein–Barr virus infection in Richter transformation. Am J Hematol 1999;60(2):99–104. DOI: 10.1002/(sici)10968652(199902)60:2<99::aidajh3>3.0.co;2t
16. Rossi D., Spina V., Deambrogi C. et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood 2011;117(12):3391–401. DOI: 10.1182/ blood201009302174
17. Mao Z., QuintanillaMartinez L., Raffeld M. et al. IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large Bcell lymphoma and Hodgkin lymphoma in association with Bcell chronic lymphocytic leukemia (BCLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007;31(10):1605–14. DOI: 10.1097/PAS.0b013e31804bdaf8
18. Fabbri G., Khiabanian H., Holmes A.B. et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013;210(11):2273–88. DOI: 10.1084/jem.20131448
19. Krober A., Seiler T., Benner A. et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100(4):1410–6.
20. Cherepakhin V., Bair S.M., Meisenholder G.W., Kipps T.J. Common clonal origin of chronic lymphocytic leukemia and highgrade lymphoma of Richter syndrome. Blood 1993;82(10):3140–7.
21. Abrisqueta P., Delgado J., Alcoceba M. et al. Clinical outcome and prognostic factors of patients with Richter syndrome: realworld study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol 2020;190(6):854–63. DOI: 10.1111/bjh.16748
22. Condoluci A., Rossi D. Biology and treatment of Richter transformation. Front Oncol 2022;12:829983. DOI: 10.3389/ fonc.2022.829983
23. Rossi D., Berra E., Cerri M. et al. Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leucemia to diffuse large Bcell lymphoma. Haematologica 2006;91(10):1405–9.
24. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9(10):749–58. DOI: 10.1038/nrc2723
25. De Paoli L., Cerri M., Monti S. et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma 2013;54(5):1087–90. DOI: 10.3109/10428194. 2012.723706
26. Fabbri G., Holmes A.B., Viganotti M. et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2017;114(14):E2911–9. DOI: 10.1073/pnas.1702564114
27. Villamor N., Conde L., Martı́nezTrillos A. et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013;27(5):1100–6. DOI: 10.1038/leu. 2012.357
28. Shanafelt T.D., Wang X.V., Kay N.E. et al. Ibrutinibrituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381(5):432–43. DOI: 10.1056/NEJMoa1817073
29. Woyach J.A., Ruppert A.S., Heerema N.A. et al. Ibrutinib regimens versus chemoimmunotherapy in older patients wituntreated CLL. N Engl J Med 2018;379(26):2517–28. DOI: 10.1056/ NEJMoa1812836
30. Seymour J.F., Kipps T.J., Eichhorst B. et al. Venetoclaxrituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018;378(12):1107–20. DOI: 10.1056/NEJMoa1713976
31. Seymour J.F., Kipps T.J., Eichhorstet B.F. et al. Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from preplanned interim analysis of the randomized phase 3 murano study. Blood 2017;130(Suppl 1):LBA2.
32. Byalik T.E. Venetoclax in treatment of chronic lymphocytic leukemia (literature review). Onkogematologiya = Oncohematology 2018;13(2):32–8. (In Russ.). DOI: 10.17650/1818834620181323238
33. Stilgenbauer S., Eichhorst B., Schetelig J. et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol 2018;36(19):1973–80. DOI: 10.1200/JCO.2017.76.6840
34. Balakrishnan K., Peluso M., Fu M. et al. The phosphoinositide3kinase (PI3K)delta and gamma inhibitor, IPI145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia 2015;29(9):1811–22. DOI: 10.1038/ leu.2015.105
35. Patel V.M., Balakrishnan K., Douglas M. et al. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT199). Leukemia 2017;31(9):1872–81. DOI: 10.1038/leu.2016.382
36. Langerbeins P., Busch R., Anheier N. et al. Poor efficacy and tolerability of RCHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol 2014;89(12):E239–43. DOI: 10.1002/ajh.23841
37. Herrera A.F., Ahn K.W., Litovich C. et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large Bcell lymphomatype Richter syndrome. Blood Adv 2021;5(18):3528–39. DOI: 10.1182/bloodadvances.2021004865
38. Bouclet F., Calleja A., Dilhuydy M.S. et al. Realworld outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Ann Hematol 2021;100(4):987–93. DOI: 10.1007/s0027702104419w
39. Iannello A., Vitale N., Coma S. et al. Synergistic efficacy of the dual PI3Kdelta/gamma inhibitor duvelisib with the Bcl2 inhibitor venetoclax in Richter syndrome PDX models. Blood 2021;137(24):3378–89. DOI: 10.1182/blood.2020010187
Review
For citations:
Rukavitsyn O.A., Pop V.P., Drozd M.V., Ryabukhina Yu.E. A clinical case of the effective combined use of BCL-2 and PI3K inhibitors in the treatment of a patient with an unfavorable chronic lymphocytic leukemia with transformation into diffuse large B-cell lymphoma (Richter’s syndrome). Oncohematology. 2022;17(4):38-47. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-4-38-47
Views:
9457
Email this article 